Combined expression analysis and SNP-based measurement of copy number variation in ovarian cancer.

结合表达分析和基于 SNP 的卵巢癌拷贝数变异测量。

• 批准号: nhmrc : 400339
• 负责人: Prof Anna Defazio
• 金额: $ 29.35万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/combined-expression-analysis-ovarian-cancer/95161
• 关键词: Combined; expression; analysis; SNP; based

For a woman with advanced ovarian cancer, the degree and duration of her response to platinum agents is probably the single most important determinant of her chance of survival for an extended period. At the moment we cannot accurately predict that response and, despite a great deal of effort, we don't understand what controls her initial response to treatment and almost inevitable relapse with platinum-refractory disease. In recent years it has become possible to measure the patterns of activity of thousands of genes simultaneously using microfabricated devices known as microarrays. As aberrant gene activity is a major determinant of tumour growth and drug sensitivity, we expect that such information will provide an insight into the dynamics of tumour growth and lead to tests that are predictive of treatment response and survival. Indeed, there are now a number of examples of solid cancers where microarray-based expression information is predictive of outcome and in breast cancer such information is being actively developed as a clinical tool. Our proposed research is based on the Australian Ovarian Cancer Study (AOCS), which is a national study established in January 2003 through a US Department of Defense CDMRP-OCRP Program grant. In just over 24 months AOCS has become the largest study of its kind in the world and represents a powerful bioresource for the molecular analysis of ovarian cancer. The objective of this application is to extend microarray analysis of AOCS serous ovarian cancer cases, particularly focusing on women with primary and acquired platinum resistance. Platinum resistance is the major barrier to long-term remissions in women with ovarian cancer. High-resolution genomic analysis of a large number of well-selected cases with linked outcome data should provide an extremely valuable molecular dataset for ovarian cancer.

对于晚期卵巢癌患者，其对铂类药物的反应程度和持续时间可能是其长期生存机会的最重要决定因素。目前，我们无法准确预测这种反应，尽管做了大量的努力，我们不明白是什么控制了她对治疗的最初反应和几乎不可避免的铂难治性疾病复发。近年来，利用被称为微阵列的微加工设备，同时测量数千个基因的活动模式已经成为可能。由于异常基因活性是肿瘤生长和药物敏感性的主要决定因素，我们期望这些信息将提供对肿瘤生长动态的洞察，并导致预测治疗反应和生存的测试。事实上，现在有许多实体癌的例子，其中基于微阵列的表达信息可以预测结果，并且在乳腺癌中，这种信息正被积极开发为临床工具。我们提出的研究是基于澳大利亚卵巢癌研究（AOCS），这是一项国家研究，成立于2003年1月通过美国国防部CDMRP-OCRP计划拨款。在短短24个月内，AOCS已成为世界上同类研究中最大的研究，并代表了卵巢癌分子分析的强大生物资源。本申请的目的是扩展AOCS浆液性卵巢癌病例的微阵列分析，特别关注原发性和获得性铂耐药的女性。铂类耐药是卵巢癌患者长期缓解的主要障碍。对大量精心挑选的病例进行高分辨率基因组分析，结果数据相关，应为卵巢癌提供极有价值的分子数据集。